Kaken Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd. (KKPCF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
kkpcf · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Kaken Pharmaceutical Co., Ltd. (KKPCF) measures how much investors pay for each dollar of the company's trailing earnings. KKPCF's current PE ratio of 67.32x is calculated by dividing its stock price of $26.78 by its TTM earnings per share of $56.59. +129.8% elevated vs 5Y avg 29.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%16.6x
MedianQ3 · 75%72.5x
Max
At 67.32x, KKPCF's current P/E is higher than in 95% of its annual fiscal year readings over the past 20 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Kaken Pharmaceutical Co., Ltd.You KKPCF | $1.0B | 67.32x | +152.2% | $56.59 |
 Adcock Ingram Holdings Limited AIHLF | $624M | 7.40x | -72.3% | $5.85 |
 Biotage AB (publ) BITGF | $1.2B | 46.23x | +73.2% | $3.55 |
 Biotest AG BTTAY | $943M | 66.05x | +147.4% | $0.35 |
 Columbia Care Inc. CCHWF | $521M | N/A | — | -$0.26 |
 China Shineway Pharmaceutical Group Limited CSWYF | $816M | 5.56x | -79.2% | $1.26 |
 Drägerwerk AG & Co. KGaA DGWPF | $1.4B | 8.23x | -69.2% | $7.44 |
Industry Average 5 peers with valid PE | — | 26.70x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 72.51x | $56.91 | +571.6% | |
2025-03-31 FY2025 | 10.80x | $365.42 | -36.8% | |
2024-03-31 FY2024 | 17.08x | $212.66 | -36.3% | |
2023-03-31 FY2023 | 26.83x | $144.79 | +39.2% | |
2022-03-31 FY2022 | 19.28x | $251.44 | +64.4% | |
2021-03-31 FY2021 | 11.72x | $347.37 | +46.7% | |
2020-03-31 FY2020 | 7.99x | $494.89 | -13.0% | |
2019-03-31 FY2019 | 9.19x | $445.78 | +10.6% | |
2018-03-31 FY2018 | 8.31x | $470.55 | +8.8% | |
2017-03-31 FY2017 | 7.64x | $536.71 | -5.9% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Kaken Pharmaceutical Co., Ltd. (KKPCF) measures how much investors pay for each dollar of the company's trailing earnings. KKPCF's current PE ratio of 67.32x is calculated by dividing its stock price of $26.78 by its TTM earnings per share of $56.59.
Frequently asked questions
KKPCF pe ratio · 6 questionsKKPCF's current PE ratio is 67.32x as of 2026-06-08, based on a stock price of $26.78 and TTM EPS of $56.59. Data sourced from Financial Modeling Prep via KKPCF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Kaken Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08